RERobert E. Emerson

Robert E. Emerson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robert E. Emerson has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Liang Cheng

    Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA

    3 shared publications
  • Fadi W. Abdul-Karim

    From the Department of Pathology and Laboratory Medicine (R.E.E., M.W., L.C.), Indiana University School of Medicine, Indianapolis, Indiana; Department of Pathology (F.L., W.D.L.), Women & Infants Hospital and Brown Medical School, Providence, Rhode Island; and Department of Pathology (F.W.A.-K.), Case Western Reserve University, Cleveland, Ohio

    2 shared publications
  • Fang Liu

    2 shared publications
  • Mingsheng Wang

    From the Department of Pathology and Laboratory Medicine (R.E.E., M.W., L.C.), Indiana University School of Medicine, Indianapolis, Indiana; Department of Pathology (F.L., W.D.L.), Women & Infants Hospital and Brown Medical School, Providence, Rhode Island; and Department of Pathology (F.W.A.-K.), Case Western Reserve University, Cleveland, Ohio

    2 shared publications
  • Qipeng Fan

    Department of Obstetrics and Gynecology, Indiana University School of Medicine, 950 W. Walnut St. R2-E380, Indianapolis, IN 46202, USA

    2 shared publications
  • Thomas M. Ulbright

    2 shared publications

Latest Publications

  • Open Access

    A Novel ZIP4-HDAC4-VEGFA Axis in High-Grade Serous Ovarian Cancer

    by Qipeng Fan, Lihong Li, Tian-Li Wang, Robert E. Emerson, Yan Xu

    We have recently identified ZIP4 as a novel cancer stem cell (CSC) marker in high-grade serous ovarian cancer (HGSOC). While it converts drug-resistance to cisplatin (CDDP), we unexpectedly found that ZIP4 induced sensitization of HGSOC cells to histone deacetylase inhibitors (HDACis). Mechanistically, ZIP4 selectively upregulated HDAC IIa HDACs, with little or no effect on HDACs in other classes. HDAC4 knockdown (KD) and LMK-235 inhibited spheroid formation in vitro and tumorigenesis in vivo, with hypoxia inducible factor-1 alpha (HIF1α) and endothelial growth factor A (VEGFA) as functional downstream mediators of HDAC4. Moreover, we found that ZIP4, HDAC4, and HIF1α were involved in regulating secreted VEGFA in HGSOC cells. Furthermore, we tested our hypothesis that co-targeting CSC via the ZIP4-HDAC4 axis and non-CSC using CDDP is necessary and highly effective by comparing the effects of ZIP4-knockout/KD, HDAC4-KD, and HDACis, in the presence or absence of CDDP on tumorigenesis in mouse models. Our results showed that the co-targeting strategy was highly effective. Finally, data from human HGSOC tissues showed that ZIP4 and HDAC4 were upregulated in a subset of recurrent tumors, justifying the clinical relevance of the study. In summary, our study provides a new mechanistic-based targeting strategy for HGSOC.


  • Open Access

    ZIP4 Is a Novel Cancer Stem Cell Marker in High-Grade Serous Ovarian Cancer

    by Qipeng Fan, Wen Zhang, Robert E. Emerson, Yan Xu

    High-grade serous ovarian cancer (HGSOC) is one of the most deadly and heterogenic cancers. We have recently shown that ZIP4 (gene name SLC39A4), a zinc transporter, is functionally involved in cancer stem cell (CSC)-related cellular activities in HGSOC. Here, we identified ZIP4 as a novel CSC marker in HGSOC. Fluorescence-activated cell sorter (FACS)-sorted ZIP4+, but not ZIP4− cells, formed spheroids and displayed self-renewing and differentiation abilities. Over-expression of ZIP4 conferred drug resistance properties in vitro. ZIP4+, but not ZIP4− cells, formed tumors/ascites in vivo. We conducted limiting dilution experiments and showed that 100–200 ZIP4+ cells from both PE04 and PEA2 cells formed larger tumors than those from 100–200 ALDH+ cells in mice. Mechanistically, we found that ZIP4 was an upstream regulator of another CSC-marker, NOTCH3, in HGSOC cells. NOTCH3 was functionally involved in spheroid formation in vitro and tumorigenesis in vivo in HGSOC. Genetic compensation studies showed that NOTCH3, but not NOTCH1, was a critical downstream mediator of ZIP4. Furthermore, NOTCH3, but not NOTCH1, physically bound to ZIP4. Collectively, our data suggest that ZIP4 is a novel CSC marker and the new ZIP4-NOTCH3 axis represents important therapeutic targets in HGSOC.


  • Open Access

    Pten and Dicer1 loss causes poorly-differentiated endometrial adenocarcinoma in mice

    by Xiyin Wang, Jillian R. H. Wendel, Robert E. Emerson, Russell R. Broaddus, Chad J. Creighton, Douglas B. Rusch, Aaron M Buechlein, Francesco J. DeMayo, John P. Lydon, Shannon M. Hawkins

    Endometrial cancer remains the most common gynecological malignancy in the United States. While the loss of the tumor suppressor, PTEN (phosphatase and tensin homolog), is well studied in endometrial cancer, recent studies suggest that DICER1 , the endoribonuclease responsible for miRNA genesis, also plays a significant role in endometrial adenocarcinoma. In an endometrial adenocarcinoma mouse model, which has a conditional uterine deletion of Pten, Dicer1 was also conditionally deleted. Conditional uterine deletion of Dicer1 and Pten resulted in high-penetrance, poorly-differentiated endometrial adenocarcinomas. Poorly-differentiated endometrial adenocarcinomas expressed known markers of clear-cell adenocarcinoma, including Napsin A and HNF1B (hepatocyte nuclear factor 1 homeobox B). Adenocarcinomas were hormone-independent, and treatment with long-term progesterone did not mitigate poorly-differentiated adenocarcinoma, nor did it affect adnexal metastasis. Transcriptomic analyses of uteri or Ishikawa cells with deletion of DICER1 revealed unique transcriptomic profiles and global downregulation of miRNAs. Integration of downregulated miRNAs with upregulated mRNA targets revealed deregulated let-7 and miR-16 target genes, similar to published human DICER1 -mutant endometrial cancers from TCGA (The Cancer Genome Atlas). Importantly, these miRNA-target genes, involved in ephrin-receptor and transforming growth factor-beta signaling, represent potential clinical targets for rare, yet deadly, poorly-differentiated endometrial adenocarcinomas in women. This mouse model represents poorly-differentiated endometrial adenocarcinoma and will allow for the discovery of novel mechanisms of hormone-independent endometrial adenocarcinoma from atrophic endometrium. Significance Statement: Endometrial cancer is one of the few cancers with an increasing death rate in the United States. The most significant risk factor associated with death is high tumor grade, which occurs most frequently in postmenopausal women, where it develops within an atrophic endometrium. Here, we present a mouse model with conditional deletion of Dicer1 , a key enzyme in miRNA genesis, and Pten , a tumor suppressor, that develops poorly-differentiated, steroid hormone-independent, endometrial adenocarcinoma with adnexal metastasis. These high-grade adenocarcinomas develop from an atrophic endometrium and share molecular features with DICER1 -mutant human endometrial adenocarcinomas. We anticipate that this preclinical model represents a move toward the discovery of novel mechanisms of hormone-independent development of endometrial adenocarcinoma from atrophic endometrium.

  • Ovary and Peritoneum

    by Robert E. Emerson

  • Premalignancy of the testis and paratestis

    by Robert E. Emerson, Liang Cheng


  • Molecular Genetic Evidence of an Independent Origin of Serous Low Malignant Potential Implants and Lymph Node Inclusions

    by Robert E. Emerson, Mingsheng Wang, Fang Liu, W. Dwayne Lawrence, Fadi W. Abdul-Karim, Liang Cheng

    Summary: Patients with ovarian serous tumors of low malignant potential (LMP) are commonly found to have peritoneal implants. Less commonly, similar lesions are seen in lymph nodes, sometimes in association with endosalpingiosis. We compared these lesions to the coexisting ovarian LMP tumors to determine whether they are clonally related to the ovarian neoplasm. Seventeen patients with serous LMP tumors present at 2 or more sites were identified. Tissue samples were microdissected from formalin-fixed paraffin-embedded tissue blocks. Samples of normal tissue, the ovarian LMP tumors, peritoneal LMP implants, and LMP inclusions within lymph nodes were obtained. Genomic DNA was extracted from the samples, and polymerase chain reaction and X-chromosome inactivation (human androgen receptor assay) analysis were performed. The pattern of X-chromosome inactivation could be determined in 15 of the 17 cases, and nonrandom X-chromosome inactivation was observed in 13 of these cases. Twelve of these cases included both ovarian and extraovarian LMP tumors. In 9 of these 12 cases, the extraovarian LMP tumor shared a similar pattern of nonrandom X-chromosome inactivation with the ovarian tumor. In these cases, the shared inactivation pattern was seen at 1 extraovarian site (3 cases), 2 extraovarian sites (4 cases), 5 extraovarian sites (1 case), and 7 of 8 extraovarian sites (1 case). In the remaining 3 cases, opposite patterns of nonrandom X-chromosome inactivation were seen. These data suggest that, in most cases, serous LMP tumor implants and lymph node inclusions share a common clonal origin with the associated ovarian tumors. However, in at least some cases, the implants and inclusions seem to arise independently from the associated ovarian serous LMP tumors.


  • Molecular Genetic Evidence Supporting the Neoplastic Nature of the Leydig Cell Component of Ovarian Sertoli-Leydig Cell Tumors

    by Robert E. Emerson, Mingsheng Wang, Lawrence M. Roth, Wenxin Zheng, Fadi W. Abdul-Karim, Fang Liu, Thomas M. Ulbright, John N. Eble, Liang Cheng

    Sertoli-Leydig cell tumors (SLCT) comprise less than 1% of ovarian tumors. The nature of the Leydig cells has been a subject of controversy and it is unclear whether they are clonally related to the neoplasm or instead proliferate as a non-neoplastic response to the Sertoli-cell component. Twelve ovarian SLCT were identified and hematoxylin and eosin and unstained sections were prepared from formalin-fixed, paraffin-embedded tissue blocks. Tissue samples were microdissected from normal tissue, the Sertoli cell component, and the Leydig cell tumor component using the laser capture microdissection method. If present, tissue was also obtained from any heterologous component. Genomic DNA was extracted from the samples and polymerase chain reaction was used to amplify polymorphic sites at 5 loci: D16S402, TP53, IFNA, D17S855, and D11S1318. X-chromosome inactivation (HUMARA) analysis was also performed. LOH and/or nonrandom X-chromosome inactivation was observed in at least 1 of the 6 amplified loci in the Leydig cell component of 10 of the 12 tumors. LOH and nonrandom X-chromosome inactivation patterns of the Sertoli cell component and Leydig cell component were compared. Concordant allelic loss and/or matching X-chromosome inactivation patterns were observed in 8 (67%) of the 12 tumors. In 7 of these tumors similar LOH or X-chromosome inactivation was observed at 1 site. In 1 tumor similar LOH and/or X-chromosome inactivation was observed at 2 sites. Three tumors had heterologous components. The heterologous components similarly shared LOH/X-chromosome inactivation with the Sertoli cell components at 1 site in 1 case and 2 sites in 2 cases. These data suggest that, at least in some cases, the Leydig cell component of SLCT is neoplastic rather than reactive in nature, and shares a common clonal origin with the coexisting Sertoli cell component. Similarly, the heterologous components, when present, appear to share clonal origin with the Sertoli cell components.


  • Endoscopic ultrasound-guided fine-needle aspiration cytology diagnosis of intraductal papillary mucinous neoplasm of the pancreas is highly predictive of pancreatic neoplasia

    by Robert E. Emerson, Melissa L. Randolph, Harvey M. Cramer

    Intraductal papillary mucinous neoplasms (IPMN) have been considered difficult to diagnose by fine‐needle aspiration (FNA) cytology. We identified 57 cases diagnosed as IPMN or consistent with IPMN by endoscopic ultrasound (EUS)‐guided FNA over a 9‐yr period. Histologic follow‐up was available for 20 patients (35%). Pancreatic neoplasia was demonstrated in 18 of these cases (90%). The histologic diagnoses were IPMN (16 cases), pancreatic intraductal neoplasia (grade 1b, 1 case), invasive mucin‐producing adenocarcinoma (1 case), and chronic pancreatitis with a pseudocyst (2 cases). Sixty‐two cases of IPMN without coexisting adenocarcinoma were diagnosed by histology during this time period. Of these, 35 (56%) had a preceding EUS‐guided FNA. The diagnosis made by EUS‐guided FNA in these 35 cases was negative or nondiagnostic (6 cases), benign cyst (1 case), chronic pancreatitis (2 cases), atypical ductal cells (2 cases), adenocarcinoma or suspicious for adenocarcinoma (3 cases), consistent with mucinous cystic neoplasm (4 cases), and IPMN or consistent with IPMN (16 cases). An EUS FNA diagnosis of probable or definite neoplasia was, therefore, made in 71% of cases of histologically proven IPMN. Diagn. Cytopathol. 2006;34:457–462.


  • Enterogenous Cysts of the Spinal Canal and Cerebellopontine Angle

    by Robert E. Emerson, Biagio Azzarelli

    Enterogenous cysts are rare, benign lesions involving the spinal canal or the cerebellopontine angle. Typically they present with compression of the spinal cord or cranial nerves. They are usually 1 cm or less in size and are typically lined by columnar mucin-producing epithelium resembling enteric epithelium or columnar ciliated epithelium resembling respiratory epithelium. The case records of the Division of Neuropathology at Indiana University were reviewed for cystic lesions of the spinal canal and cranial cavity for a 26-year period. Seven surgically resected enterogenous cysts were identified. The original slides were studied. Additional sections were stained with mucicarmine, and immunohistochemical stains including thyroid transcription factor 1, epithelial membrane antigen, and cytokeratin 5/6 (CK5/6) were performed. Electron microscopy was performed in 1 case. The cysts ranged in size from 4 to 10 mm. One had stratified cuboidal epithelium, 1 had ciliated columnar and stratified squamous epithelium, 1 had columnar mucinous epithelium, and 4 had ciliated columnar epithelium. Epithelial membrane antigen and CK5/6 positivity were observed in all cases. Strong CK5/6 positivity was seen in the basal cells, with little or no immunoreactivity in the ciliated cells. Mucicarmine positivity was observed in 4 cases, and thyroid transcription factor 1 positivity was observed in 2 cases. Electron microscopy demonstrated well-developed stereocilia, distinct basal cells, and a thin basement membrane. The histopathologic, ultrastructural, and immunologic findings in these lesions are similar to those present in the bronchial epithelium, supporting the hypothesis of endodermal origin for these lesions.